Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check4 days agoChange DetectedDifference0.2%

- Check12 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedAdded Revision: v3.4.2; deleted the notices for Revision: v3.4.1 and the government funding lapse notice.SummaryDifference0.3%

- Check47 days agoChange DetectedSite-wide notice added about a lapse in government funding and NIH Clinical Center operations; Revision: v3.4.1 replaces v3.4.0.SummaryDifference0.3%

- Check55 days agoChange DetectedUI updates include displaying the glossary toggle and adding a 'Last Update Submitted that Met QC Criteria' label, and a 'No FEAR Act Data' note was added with the revision bumped to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange DetectedRevision from v3.3.3 to v3.3.4 represents a minor update to the page, with no changes to study details or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.